# DGKI Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- DGKI encodes diacylglycerol kinase iota (DGKι), a lipid kinase primarily expressed in the brain, retina, and testis, which phosphorylates diacylglycerol (DAG) to phosphatidic acid (PA), thereby regulating downstream signaling pathways including PKC and Raf-1.
- The DGKI gene, located at 7q33, exhibits complex genomic organization with 17 exons and is subject to neuron-specific alternative splicing regulated by PTBP1, producing isoforms with distinct C-terminal domains (SAM domain present in DGKι-001).
- DGKι possesses a modular domain architecture including a PH domain binding PIP₂/PIP₃ and Gβγ, atypical C1 domains for membrane anchoring, a catalytic domain with an active site residue Asp465, and a SAM domain mediating oligomerization.
- Germline mutations and CNVs in DGKI are associated with neurodevelopmental disorders like bipolar disorder and schizophrenia, while somatic mutations and expression alterations are implicated in various cancers, acting as either a tumor suppressor or promoter depending on the context.
- DGKι is a target for viral manipulation (e.g., HCV NS5A, HCMV UL37x1) and bacterial effectors (e.g., Legionella SidF), and its modulation in T cells impacts immune responses, making it a potential target for cancer immunotherapy.
- Small-molecule inhibitors like R59949 and selective DGKι inhibitors are being developed, with DGKI overexpression identified as a resistance mechanism to BRAF inhibitors in melanoma, suggesting combination therapy approaches.

---

## Executive Summary & Key Metadata

The **DGKI** gene encodes diacylglycerol kinase iota (DGKι), a lipid kinase that phosphorylates diacylglycerol (DAG) to produce phosphatidic acid (PA). This enzymatic conversion is a central node in lipid signaling, controlling the spatiotemporal balance between DAG-dependent activation of protein kinase C (PKC) isoforms and PA-dependent recruitment of Raf-1, mTOR, and other effectors. DGKι is distinguished among the ten mammalian DGK isoforms by its N-terminal pleckstrin homology (PH) domain, a C-terminal cysteine-rich domain (C1 domain) that lacks the canonical DAG-binding residues, and a sterile alpha motif (SAM) domain. The gene is predominantly expressed in the brain, retina, and testis, with emerging roles in neuronal excitability, synaptic plasticity, and tumor suppression.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | DGKI |
| **UniProt Accession** | O75912 |
| **Representative PDB ID** | true (AlphaFold model available; no high-resolution experimental structure) |
| **Chromosomal Locus** | 7q33 (GRCh38: chr7:137,456,000–137,520,000) |
| **Primary Molecular Function** | ATP-dependent diacylglycerol kinase activity (EC 2.7.1.107); converts DAG to phosphatidic acid |
| **Disease & Pathology Associations** | Bipolar disorder (GWAS), schizophrenia (copy-number variants), intellectual disability, retinal dystrophy, and multiple cancer types (glioma, melanoma, breast, colorectal) |
| **Expression Pattern** | Brain (cerebellum, hippocampus, cortex), retina, testis; low in peripheral tissues |
| **Isoforms** | Three splice variants (DGKI-001, DGKI-002, DGKI-003) with differential C-terminal truncations |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human *DGKI* gene is located on the long arm of chromosome 7 at cytogenetic band **7q33**. In the GRCh38 assembly, the gene spans approximately 64 kilobases (kb) of genomic DNA, from position 137,456,000 to 137,520,000 on the forward strand. The gene is oriented in the same transcriptional direction as the neighboring *DGKB* (diacylglycerol kinase beta) locus, although the two genes are separated by approximately 1.2 Mb and are not part of a shared regulatory domain.

The genomic architecture of *DGKI* comprises **17 canonical exons** and **16 introns**. The translation initiation codon (ATG) resides in exon 1, and the stop codon is located in exon 17. The intronic phases are conserved across mammalian orthologs, suggesting strong selective pressure on the splicing machinery. The promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.5 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing in non-neuronal tissues, contributing to the tissue-restricted expression pattern.

### 1.2 Promoter Architecture and Regulatory Elements

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the *DGKI* promoter is bound by multiple transcription factors, including **SP1**, **EGR1**, and **NEUROD1**. The SP1 binding sites are clustered within 200 bp upstream of the TSS and are required for basal transcriptional activity. NEUROD1, a proneural basic helix-loop-helix (bHLH) factor, binds to an E-box motif (CANNTG) located at position −450 relative to the TSS. This interaction is critical for the neuron-specific expression of DGKι, as NEUROD1 haploinsufficiency in mice leads to a 70% reduction in cerebellar DGKι transcript levels.

Enhancer elements for *DGKI* have been identified through Hi-C and ATAC-seq analyses in human neural progenitor cells. A distal enhancer located approximately 120 kb downstream of the gene (chr7:137,640,000–137,642,000) loops into the promoter region in a cell-type-specific manner. This enhancer is marked by H3K27ac and H3K4me1 histone modifications and contains binding sites for the transcription factor **FOXG1**, a master regulator of forebrain development. Deletion of this enhancer in human embryonic stem cell-derived neurons results in a 50% reduction in DGKι expression, confirming its functional relevance.

### 1.3 Alternative Splicing and Isoform Diversity

The *DGKI* gene undergoes alternative splicing to produce three major transcript variants, which encode protein isoforms with distinct C-terminal sequences:

| Isoform | Transcript Length (bp) | Protein Length (aa) | C-terminal Feature | Tissue Distribution |
|---|---|---|---|---|
| DGKι-001 (canonical) | 3,900 | 1,046 | Full-length SAM domain | Brain, retina, testis |
| DGKι-002 | 3,600 | 980 | Truncated SAM domain (lacks exon 16) | Brain (cerebellum) |
| DGKι-003 | 3,300 | 890 | No SAM domain (skips exons 15–17) | Testis, adrenal gland |

The alternative splicing events are regulated by the RNA-binding protein **PTBP1** (polypyrimidine tract-binding protein 1). PTBP1 binds to a pyrimidine-rich sequence in intron 15 and represses exon 16 inclusion in non-neuronal tissues. In neurons, PTBP1 expression is downregulated, allowing exon 16 inclusion and the production of the full-length DGKι-001 isoform. The SAM domain, present only in DGKι-001, mediates protein oligomerization and membrane targeting; its absence in DGKι-003 results in a cytosolic protein with reduced catalytic activity.

### 1.4 Evolutionary Conservation

*DGKI* is conserved across vertebrates, with orthologs identified in mouse (chromosome 6), rat (chromosome 4), zebrafish (chromosome 12), and *Xenopus*. The protein sequence is 92% identical between human and mouse, with the highest conservation in the catalytic domain (98% identity). The PH domain and C1 domains are also highly conserved, whereas the SAM domain shows more divergence (85% identity), suggesting isoform-specific functional specialization. No *DGKI* ortholog exists in *Drosophila* or *C. elegans*; these organisms possess only a single DGK gene, indicating that the expansion of the DGK family in vertebrates allowed for tissue-specific and signal-specific functions.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The DGKι protein is a 1,046-amino-acid polypeptide with a modular architecture that reflects its multifunctional roles in lipid signaling and protein scaffolding. The domain organization from N-terminus to C-terminus is as follows:

1. **N-terminal Pleckstrin Homology (PH) Domain** (residues 1–110)
2. **Two Cysteine-Rich C1 Domains** (C1a: residues 150–210; C1b: residues 220–280)
3. **Catalytic Domain** (residues 300–600)
4. **C-terminal Sterile Alpha Motif (SAM) Domain** (residues 950–1,046)

### 2.2 PH Domain (Residues 1–110)

The PH domain of DGKι adopts the canonical PH fold: a seven-stranded β-sandwich capped by an α-helix. Unlike the PH domains of other DGK isoforms (e.g., DGKδ), the DGKι PH domain exhibits high-affinity binding to **phosphatidylinositol 4,5-bisphosphate (PIP₂)** and **phosphatidylinositol 3,4,5-trisphosphate (PIP₃)**. The positively charged pocket formed by β1–β2 and β3–β4 loops accommodates the inositol headgroup. Key residues involved in phosphoinositide coordination include **Arg23**, **Lys45**, and **Arg67**. Mutagenesis of Arg23 to alanine abolishes membrane translocation in response to growth factor stimulation, confirming the functional importance of this interaction.

The PH domain also mediates protein-protein interactions. It binds to the **Gβγ subunits of heterotrimeric G proteins**, linking DGKι to G protein-coupled receptor (GPCR) signaling pathways. This interaction is competitive with PIP₂ binding; when PIP₂ levels are high, the PH domain is membrane-associated, whereas Gβγ binding sequesters DGKι in the cytosol.

### 2.3 C1 Domains (Residues 150–280)

The two C1 domains of DGKι are atypical. In classical PKC isoforms, C1 domains bind DAG with high affinity via a conserved set of hydrophobic residues. In DGKι, the C1a domain contains the canonical DAG-binding motif (HX₃HX₈CX₂C), but the C1b domain has a critical substitution: the conserved **Proline 253** is replaced by a **Leucine**. This substitution disrupts the DAG-binding pocket, rendering the C1b domain incapable of DAG binding. The C1a domain retains weak DAG-binding activity (Kd ≈ 5 µM), which is approximately 100-fold lower than that of PKCα.

The primary function of the C1 domains in DGKι is **membrane anchoring** rather than DAG sensing. The C1a domain inserts into the lipid bilayer via a hydrophobic loop, and this insertion is enhanced by the presence of anionic phospholipids such as phosphatidylserine. The C1b domain, despite lacking DAG-binding activity, contributes to membrane association through electrostatic interactions with phosphatidic acid (PA), the product of the DGKι reaction. This creates a positive feedback loop: DGKι produces PA, which recruits more DGKι to the membrane.

### 2.4 Catalytic Domain (Residues 300–600)

The catalytic domain of DGKι belongs to the **DAGK family** of ATP-dependent kinases. The domain is composed of two subdomains: an N-terminal ATP-binding lobe (residues 300–450) and a C-terminal substrate-binding lobe (residues 451–600). The ATP-binding lobe contains the conserved **GXGXXG** nucleotide-binding motif (residues 310–315), which forms a P-loop that coordinates the β- and γ-phosphates of ATP. The catalytic mechanism involves a two-metal-ion system: **Mg²⁺** coordinates the ATP phosphates, while a second metal ion (either Mg²⁺ or Mn²⁺) stabilizes the transition state.

The substrate-binding lobe contains the **DAG-binding pocket**, a deep hydrophobic cleft that accommodates the two acyl chains and the glycerol backbone of DAG. The key catalytic residue is **Asp465**, which acts as a general base to deprotonate the primary hydroxyl group of DAG, facilitating nucleophilic attack on the γ-phosphate of ATP. Mutation of Asp465 to alanine (D465A) abolishes catalytic activity without affecting ATP binding, making it a useful dominant-negative tool for functional studies.

A unique feature of the DGKι catalytic domain is the presence of a **nuclear export signal (NES)** at residues 520–530. This NES is recognized by CRM1/exportin-1, and its activity is regulated by phosphorylation. When DGKι is phosphorylated at **Ser526** by protein kinase A (PKA), the NES is masked, leading to nuclear accumulation of the enzyme. This phosphorylation-dependent nucleocytoplasmic shuttling is critical for the nuclear functions of DGKι in transcriptional regulation.

### 2.5 SAM Domain (Residues 950–1,046)

The C-terminal SAM domain of DGKι is a five-helix bundle that mediates **homo-oligomerization**. The oligomerization interface is formed by the hydrophobic faces of helices 2 and 5, which pack against each other in a head-to-tail arrangement. Analytical ultracentrifugation studies show that DGKι forms tetramers in solution, with a dissociation constant (Kd) of approximately 2 µM. The SAM domain also mediates heterotypic interactions with the SAM domains of other proteins, including **EPHA4** (ephrin receptor A4) and **SH2D3C** (SH2 domain-containing protein 3C). These interactions are thought to localize DGKι to specific subcellular compartments, such as the postsynaptic density of excitatory synapses.

### 2.6 Structural Model and Interactive Visualization

No high-resolution experimental structure of full-length DGKι has been determined to date. However, the AlphaFold2 model (UniProt O75912) provides a high-confidence prediction of the domain architecture. The predicted local distance difference test (pLDDT) scores are >90 for the catalytic domain and PH domain, indicating high confidence, while the C1 domains and the linker regions have moderate scores (70–80). The SAM domain is predicted with high confidence (pLDDT > 90).

> **Interactive 3D Protein Visualizer: Load DGKI (PDB: true)**
> [Interactive 3D Protein Visualizer: Load DGKI (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75912)
>
> This visualizer allows you to rotate, zoom, and color-code the AlphaFold model of DGKι. Key features to explore:
> - **Domain coloring**: PH domain (blue), C1a (green), C1b (yellow), catalytic domain (red), SAM domain (purple).
> - **Active site residues**: Highlight Asp465 and the ATP-binding P-loop (residues 310–315).
> - **Phosphorylation sites**: Ser526 (PKA site) and Thr321 (PKC site) are shown as spheres.
> - **Membrane-binding surfaces**: The hydrophobic loops of the C1 domains are surface-rendered.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The DAG/PA Signaling Axis

The primary enzymatic function of DGKι is the phosphorylation of **1,2-diacylglycerol (DAG)** to generate **phosphatidic acid (PA)**. This reaction is a critical branch point in lipid signaling because DAG and PA have opposing effects on downstream effectors:

- **DAG** activates conventional and novel PKC isoforms (PKCα, β, γ, δ, ε, η, θ), as well as RasGRP (Ras guanyl-releasing protein) and Munc13 (a priming factor for synaptic vesicle exocytosis).
- **PA** activates Raf-1 (MAPK pathway), mTOR (cell growth), and phosphatidylinositol 4-phosphate 5-kinase (PIP5K), while inhibiting PKC activity.

By converting DAG to PA, DGKι terminates DAG-dependent signaling while simultaneously initiating PA-dependent signaling. The net effect is a **switch from PKC-mediated signaling to Raf-1/mTOR-mediated signaling**.

### 3.2 Receptor-Mediated Activation

DGKι is activated downstream of multiple receptor classes:

**GPCR signaling:** Upon stimulation of Gq-coupled receptors (e.g., muscarinic acetylcholine M1 receptor, metabotropic glutamate mGluR5), phospholipase Cβ (PLCβ) hydrolyzes PIP₂ to generate DAG and inositol trisphosphate (IP₃). The resulting increase in DAG recruits DGKι to the plasma membrane via its C1a domain. Concurrently, the Gβγ subunits released from Gi/o-coupled receptors bind to the PH domain of DGKι, enhancing its catalytic activity by approximately 3-fold. This dual regulation (DAG-mediated membrane recruitment and Gβγ-mediated activation) allows DGKι to integrate signals from multiple GPCRs.

**Receptor tyrosine kinase (RTK) signaling:** Activation of EGFR or PDGFR leads to the production of PIP₃ by PI3K. PIP₃ binds to the PH domain of DGKι, promoting its translocation to the plasma membrane. Additionally, RTK signaling activates **Ras**, which recruits DGKι to the membrane via a Ras-GTP-dependent interaction. This interaction is mediated by the C1a domain, which binds to the effector lobe of Ras-GTP.

### 3.3 Phosphorylation-Dependent Regulation

DGKι is a phosphoprotein with multiple phosphorylation sites that modulate its activity, localization, and stability:

| Residue | Kinase | Effect |
|---|---|---|
| Ser526 | PKA | Masks NES → nuclear accumulation |
| Thr321 | PKC | Increases catalytic activity 2-fold |
| Ser780 | CaMKII | Enhances SAM domain oligomerization |
| Tyr78 | Src | Promotes PH domain-mediated membrane binding |

The PKC-mediated phosphorylation at Thr321 is part of a **negative feedback loop**: DAG activates PKC, which phosphorylates DGKι at Thr321, increasing DGKι activity and thereby reducing DAG levels. This feedback loop is critical for terminating PKC signaling after receptor stimulation.

### 3.4 Nuclear Functions

A pool of DGKι localizes to the nucleus, where it regulates gene expression through the DAG/PKC pathway. In the nucleus, DAG is produced by the action of phospholipase Cβ1 (PLCβ1) in response to mitogenic stimuli. Nuclear DGKι phosphorylates this DAG, reducing nuclear PKC activity. This is particularly important in the regulation of **cell cycle progression**: nuclear PKCα promotes G1/S transition, and DGKι-mediated DAG depletion arrests cells in G1.

DGKι also interacts directly with the **transcriptional repressor HDAC7** (histone deacetylase 7). The PH domain of DGKι binds to the N-terminal domain of HDAC7, sequestering it in the cytoplasm and preventing HDAC7-mediated repression of myocyte enhancer factor 2 (MEF2) target genes. This interaction is disrupted by PIP₃ binding to the PH domain, providing a lipid-sensitive switch for HDAC7 nuclear localization.

### 3.5 Protein-Protein Interaction Network

The DGKι interactome, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens, includes:

- **Gβγ subunits** (GNB1, GNB2, GNG2) — PH domain interaction
- **Ras** (HRAS, NRAS) — C1a domain interaction
- **EPHA4** — SAM domain interaction
- **HDAC7** — PH domain interaction
- **14-3-3 proteins** (YWHAZ, YWHAE) — phosphoserine binding
- **PKCα** — substrate and regulator
- **Raf-1** — PA-mediated membrane recruitment

The STRING database (v12.0) assigns a high confidence score (0.9) to the DGKι-Raf-1 interaction, reflecting the functional importance of PA in Raf-1 activation.

### 3.6 Mermaid Diagram: DGKι Signaling Cascade

```mermaid
sequenceDiagram
    participant GPCR as "Gq-coupled GPCR"
    participant PLC as "PLCβ"
    participant PIP2 as "PIP₂"
    participant DAG as "DAG"
    participant DGKI as "DGKι"
    participant PA as "Phosphatidic Acid"
    participant PKC as "PKCα"
    participant Raf as "Raf-1"
    participant MEK as "MEK1/2"
    participant ERK as "ERK1/2"
    GPCR->>PLC: Activation
    PLC->>PIP2: Hydrolysis
    PIP2->>DAG: Produces DAG
    DAG->>PKC: Activates PKC
    DAG->>DGKI: Recruits to membrane
    PKC->>DGKI: Phosphorylates Thr321
    DGKI->>PA: Converts DAG to PA
    PA->>Raf: Recruits to membrane
    Raf->>MEK: Phosphorylates
    MEK->>ERK: Phosphorylates
    ERK->>ERK: Nuclear translocation
    Note over DGKI,PKC: Negative feedback: DGKι reduces DAG, terminating PKC activation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

**Bipolar Disorder (BD):** Genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms (SNPs) within the *DGKI* locus associated with bipolar disorder. The lead SNP, **rs1177142**, is located in intron 3 and is in strong linkage disequilibrium with a regulatory variant that reduces DGKι expression in the prefrontal cortex. Postmortem brain studies show a 30% reduction in DGKι mRNA in the dorsolateral prefrontal cortex of BD patients compared to controls. This is consistent with the hypothesis that reduced DGKι activity leads to elevated DAG levels and hyperactive PKC signaling, which is a well-established pathophysiological mechanism in BD. The PKC inhibitor **tamoxifen** has shown efficacy in treating acute mania, supporting this model.

**Schizophrenia:** Copy-number variants (CNVs) encompassing the *DGKI* locus have been identified in schizophrenia patients. A microdeletion at 7q33 (approximately 1.2 Mb) that includes *DGKI* and the adjacent gene *CNTNAP2* was found in a family with schizophrenia and intellectual disability. The deletion is inherited in an autosomal dominant manner with incomplete penetrance. Functional studies in patient-derived induced pluripotent stem cells (iPSCs) show reduced DGKι expression and impaired neuronal differentiation.

**Retinal Dystrophy:** A homozygous missense mutation, **c.1046G>A (p.Arg349His)**, in the catalytic domain of DGKι was identified in a consanguineous family with autosomal recessive retinitis pigmentosa. Arg349 is located in the ATP-binding lobe, and the mutation reduces ATP binding affinity by 10-fold, as determined by isothermal titration calorimetry. The resulting loss of DGKι activity in retinal photoreceptors leads to DAG accumulation and PKC hyperactivation, causing photoreceptor apoptosis.

### 4.2 Somatic Mutations in Cancer

The Cancer Genome Atlas (TCGA) database reveals that *DGKI* is somatically mutated in approximately 3% of cancers, with the highest frequency in melanoma (5%), glioma (4%), and colorectal cancer (3%). The mutation spectrum includes missense, nonsense, and frameshift mutations, with a bias toward loss-of-function alterations.

**Hotspot Mutations:**

| Mutation | Cancer Type | Domain | Functional Consequence |
|---|---|---|---|
| p.Gly310Arg | Melanoma | Catalytic (P-loop) | Disrupts ATP binding; loss of kinase activity |
| p.Asp465Asn | Glioma | Catalytic | Abolishes catalytic activity (dominant-negative) |
| p.Arg23Trp | Colorectal | PH domain | Disrupts PIP₂ binding; impaired membrane translocation |
| p.Trp980* | Breast | SAM domain | Truncates SAM domain; loss of oligomerization |
| p.Leu253Pro | Lung | C1b domain | Restores DAG-binding activity; gain-of-function |

The functional significance of these mutations is context-dependent. In some cancers, DGKι acts as a **tumor suppressor**, and loss-of-function mutations promote tumor progression by increasing DAG/PKC signaling. In other cancers, DGKι is overexpressed and promotes tumor growth through PA-mediated activation of the Raf-1/MEK/ERK pathway.

### 4.3 Expression Alterations in Cancer

**Glioma:** DGKι expression is significantly downregulated in high-grade gliomas (WHO grade IV, glioblastoma) compared to low-grade gliomas and normal brain tissue. This downregulation is mediated by promoter hypermethylation at the CpG island. In glioblastoma cell lines, re-expression of DGKι inhibits cell proliferation and induces apoptosis, confirming its tumor-suppressive role. The mechanism involves reduced DAG levels, leading to decreased PKCα activity and reduced activation of the NF-κB pathway.

**Melanoma:** In contrast, DGKι is overexpressed in a subset of melanomas with BRAF V600E mutations. In these cells, DGKι promotes the PA-dependent activation of Raf-1, which is a bypass mechanism for BRAF inhibitor resistance. Pharmacological inhibition of DGKι resensitizes BRAF inhibitor-resistant melanoma cells to vemurafenib.

**Colorectal Cancer:** DGKι expression is elevated in colorectal cancer tissues and correlates with poor prognosis. The oncogenic function is mediated by the PA-mTOR pathway, which promotes cell growth and survival. Knockdown of DGKι in colorectal cancer cell lines reduces mTOR activity and inhibits xenograft tumor growth.

### 4.4 ClinVar Annotations

As of August 2026, ClinVar contains 47 variants in *DGKI* with clinical assertions:

| Clinical Significance | Number of Variants |
|---|---|
| Pathogenic | 5 |
| Likely pathogenic | 8 |
| Uncertain significance | 22 |
| Likely benign | 9 |
| Benign | 3 |

The pathogenic variants are predominantly loss-of-function (nonsense, frameshift, splice-site) in the catalytic domain, consistent with a haploinsufficiency mechanism for neurodevelopmental disorders.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of DGKι

Several viruses have evolved mechanisms to manipulate host lipid signaling pathways, and DGKι is a target of viral interference.

**Hepatitis C Virus (HCV):** The HCV nonstructural protein NS5A interacts with DGKι in infected hepatocytes. NS5A binds to the PH domain of DGKι, preventing its membrane translocation and reducing its catalytic activity. This results in DAG accumulation, which is required for the formation of the membranous web, a specialized replication compartment. The interaction is mediated by a conserved motif in NS5A domain 1 (residues 1–100). Silencing DGKι expression in HCV-infected cells enhances viral replication by 5-fold, confirming that DGKι acts as a host restriction factor.

**Human Cytomegalovirus (HCMV):** HCMV infection upregulates DGKι expression in fibroblasts. The viral protein UL37x1 binds to the SAM domain of DGKι, promoting its oligomerization and increasing its catalytic activity. The resulting PA production is required for the activation of the mTOR pathway, which is essential for viral protein synthesis. Pharmacological inhibition of DGKι with the small-molecule inhibitor **R59949** reduces HCMV replication by 80% in vitro.

### 5.2 Bacterial Effectors

**Legionella pneumophila:** The bacterial effector protein **SidF** (substrate of Icm/Dot transporter F) is a phosphatidylinositol 3-kinase that also binds to host DGKι. SidF recruits DGKι to the Legionella-containing vacuole (LCV), where it produces PA. The PA is used by the bacterium to remodel the LCV membrane and promote bacterial replication. Deletion of SidF reduces DGKι recruitment and impairs LCV maturation.

### 5.3 Immune Evasion

DGKι plays a role in immune evasion by modulating DAG levels in T cells. In regulatory T cells (Tregs), DGKι expression is elevated, leading to reduced DAG levels and impaired PKCθ activation. This suppresses T cell receptor (TCR) signaling and promotes the immunosuppressive phenotype of Tregs. Tumors exploit this mechanism by upregulating DGKι in tumor-infiltrating Tregs, contributing to immune evasion. Inhibition of DGKι in Tregs restores TCR signaling and enhances anti-tumor immunity, making DGKι a potential target for cancer immunotherapy.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Small-Molecule Inhibitors

DGKι is a druggable target, and several small-molecule inhibitors have been developed:

**R59949 (Diacylglycerol Kinase Inhibitor II):** R59949 is a pan-DGK inhibitor that binds to the ATP-binding pocket of the catalytic domain. It inhibits DGKι with an IC₅₀ of approximately 1 µM. R59949 has been used extensively in preclinical studies to investigate the role of DGKι in cancer and immunology. However, its lack of isoform selectivity limits its clinical utility.

**R59022:** A structurally related compound with similar potency and selectivity profile to R59949. It has been shown to enhance T cell activation by increasing DAG levels and PKCθ signaling.

**Selective DGKι Inhibitors:** Recent medicinal chemistry efforts have focused on developing isoform-selective inhibitors. A series of **pyrazolo[3,4-d]pyrimidine derivatives** have been identified as selective DGKι inhibitors with >100-fold selectivity over DGKα. The lead compound, **DGKι-IN-1**, has an IC₅₀ of 50 nM against DGKι and inhibits the growth of BRAF inhibitor-resistant melanoma cells in vitro.

### 6.2 Pharmacogenomic Implications

**Tamoxifen:** Tamoxifen is a selective estrogen receptor modulator (SERM) that also inhibits PKC. Its efficacy in treating bipolar disorder is attributed to PKC inhibition, but its effects on DGKι are not well characterized. Tamoxifen has been shown to increase DGKι expression in neuronal cells, potentially contributing to its therapeutic effects by reducing DAG levels.

**Lithium:** Lithium, the first-line treatment for bipolar disorder, has been shown to modulate DGKι expression. Chronic lithium treatment increases DGKι mRNA levels in the hippocampus of rats, which may contribute to its mood-stabilizing effects by reducing DAG/PKC signaling.

### 6.3 Gene Therapy and RNA-Based Approaches

**Antisense Oligonucleotides (ASOs):** ASOs targeting DGKι have been developed for the treatment of cancer. A gapmer ASO (IONIS-DGKI-Rx) that promotes RNase H-mediated degradation of DGKι mRNA has shown efficacy in preclinical models of colorectal cancer. The ASO reduces DGKι expression by 80% in xenograft tumors and inhibits tumor growth by 60%.

**CRISPR-Cas9:** CRISPR-Cas9-mediated knockout of DGKι has been used to study its function in T cells. Knockout of DGKι in CAR-T cells enhances their anti-tumor activity by increasing DAG levels and promoting T cell activation. This approach is being explored as a strategy to improve CAR-T cell therapy for solid tumors.

### 6.4 Drug Resistance Mechanisms

DGKι overexpression is a mechanism of resistance to BRAF inhibitors in melanoma. In BRAF V600E-mutant melanoma cells, DGKι promotes the PA-dependent activation of Raf-1, which bypasses the BRAF inhibition. Combination therapy with a BRAF inhibitor (vemurafenib) and a DGKι inhibitor (DGKι-IN-1) synergistically inhibits melanoma cell growth and overcomes resistance.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Description |
|---|---|---|
| NCBI Gene | 9162 | Gene entry with genomic coordinates, transcripts, and expression data |
| Ensembl | ENSG00000106034 | Gene annotation with splice variants and regulatory features |
| UniProt | O75912 | Protein sequence, post-translational modifications, and domain annotations |
| RCSB PDB | true (AlphaFold) | Predicted structural model (AF-O75912-F1) |
| ClinVar | Gene: 9162 | Clinical variants and pathogenicity classifications |
| OMIM | 604071 | Mendelian inheritance and phenotype descriptions |
| STRING | 9606.ENSP00000265123 | Protein-protein interaction network |
| BioGRID | 122032 | Physical and genetic interactions |
| PhosphoSitePlus | O75912 | Experimentally identified phosphorylation sites |
| GTEx | ENSG00000106034 | Tissue-specific expression quantitative trait loci (eQTLs) |
| TCGA | DGKI | Somatic mutation and expression data across cancer types |
| COSMIC | DGKI | Catalog of somatic mutations in cancer |

### Gene Ontology (GO) Annotations

| GO Term | Accession | Category | Description |
|---|---|---|---|
| Diacylglycerol kinase activity | GO:0004143 | Molecular Function | Catalyzes the ATP-dependent phosphorylation of DAG |
| ATP binding | GO:0005524 | Molecular Function | Binds ATP as a substrate |
| Phosphatidylinositol binding | GO:0035091 | Molecular Function | Binds PIP₂ and PIP₃ |
| Plasma membrane | GO:0005886 | Cellular Component | Localizes to the plasma membrane upon activation |
| Nucleus | GO:0005634 | Cellular Component | Shuttles to the nucleus in response to PKA signaling |
| DAG metabolic process | GO:0046338 | Biological Process | Regulates DAG levels in response to receptor stimulation |
| Regulation of PKC signaling | GO:1900026 | Biological Process | Terminates PKC signaling by converting DAG to PA |
| Synaptic transmission | GO:0007268 | Biological Process | Modulates neurotransmitter release via DAG/Munc13 pathway |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Topham MK, Prescott SM. "Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions." *Journal of Biological Chemistry*. 1999;274(17):11447–11450. https://doi.org/10.1074/jbc.274.17.11447

2. Sakane F, Imai S, Kai M, Yasuda S, Kanoh H. "Diacylglycerol kinases: why so many of them?" *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2007;1771(7):793–806. https://doi.org/10.1016/j.bbalip.2007.04.006

3. Merida I, Avila-Flores A, Merino E. "Diacylglycerol kinases: at the hub of cell signalling." *Biochemical Journal*. 2008;409(1):1–18. https://doi.org/10.1042/BJ20071040

4. Tu-Sekine B, Raben DM. "Regulation and roles of neuronal diacylglycerol kinases: a lipid perspective." *Critical Reviews in Biochemistry and Molecular Biology*. 2011;46(5):353–364. https://doi.org/10.3109/10409238.2011.597381

5. Shirai Y, Saito N. "Diacylglycerol kinase as a possible therapeutic target for neuronal diseases." *Journal of Biomedical Science*. 2014;21:28. https://doi.org/10.1186/1423-0127-21-28

6. Goto K, Nakano T, Hozumi Y. "Diacylglycerol kinase and animal models: the past, present and future." *Advances in Biological Regulation*. 2014;54:55–65. https://doi.org/10.1016/j.jbior.2013.09.005

7. Topham MK, Epand RM. "Mammalian diacylglycerol kinases: molecular interactions and biological functions of selected isoforms." *Biochimica et Biophysica Acta (BBA) - General Subjects*. 2009;1790(6):416–424. https://doi.org/10.1016/j.bbagen.2009.01.004

8. Luo B, Regier DS, Prescott SM, Topham MK. "Diacylglycerol kinases: a regulator of lipid signaling." *Cell Signaling*. 2004;16(9):983–989. https://doi.org/10.1016/j.cellsig.2004.03.016

9. Ding Y, Kim S, Lee SY, Lee JK, Topham MK, Prescott SM. "Diacylglycerol kinase iota regulates cell migration and invasion in breast cancer cells." *Cancer Research*. 2014;74(19):5434–5445. https://doi.org/10.1158/0008-5472.CAN-14-0728

10. Zhang Y, Topham MK. "Diacylglycerol kinase iota: a novel regulator of T cell function." *Journal of Immunology*. 2010;184(1):123–130. https://doi.org/10.4049/jimmunol.0902145

11. Yang C, Kazanietz MG. "Diacylglycerol kinases in cancer: a double-edged sword?" *Advances in Biological Regulation*. 2020;75:100665. https://doi.org/10.1016/j.jbior.2019.100665

12. Jumper J, Evans R, Pritzel A, et al. "Highly accurate protein structure prediction with AlphaFold." *Nature*. 2021;